MS-Lifer

The MS Lifer App is a digital assistant for the management of multiple sclerosis (MS) patients. There you will find evolutionary charts of the Expanded Disability Status Scale (EDSS) and will assist you in reassessing at each visit. In addition, you will be able to obtain PROs ("Patient Reported Outcomes") in aspects such as quality of life, depression and fatigue using scales validated in MS. MS-Lifer will allow you to calculate the dose of Cladribine tablets and access content and news about the pathology. Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune disease that affects the central nervous system (CNS) (1). More than 2.3 million people have MS worldwide (2). Most are diagnosed between the ages of 20 and 40. It is the most frequent non-traumatic disabling neurological disease in young adults (3). There is currently no cure for MS. In fact, no one knows exactly what causes it (3). At Merck we have supported people with MS for more than 20 years and we remain committed to offering solutions that increase the quality of life of those with MS by addressing their unmet medical needs (4). For this reason, we have created an exclusive assistant to support doctors in monitoring their multiple sclerosis patients, the MS Lifer app. In it you can calculate the progression of the disability through the EDSS scale. You will be able to make a graph in each query. It's also a valuable tool that gives you the option of getting metrics on things like quality of life, depression, and fatigue. In addition, you will be able to calculate the dose of Cladribine tablets and you will receive content and news about the pathology. Bibliographic references: 1.MS Society UK. diagnosis | Multiple Sclerosis [Internet]. [cited 2022 Jul 27]. Available from: https://www.mssociety.org.uk/about-ms/diagnosis. 2. MS International Federation. Number of people with MS | Atlas of MS [Internet]. [cited 2022 Jul 27]. Available from: https://www.atlasofms.org/map/global/epidemiology/number-of-people-with-ms 3. National Institute of Neurological Disorders and Stroke (NIH). Multiple Sclerosis: Hope Through Research [Internet]. 2022 [cited 2022 Jul 27]. Available from: https://www.ninds.nih.gov/health-information/patient-caregiver-education/hope-through-research/multiple-sclerosis-hope-through-research 4.Merck Spain. Multiple Sclerosis - Experience [Internet]. [cited 2022 Jul 27]. Available from: https://www.merckgroup.com/es-es/expertise/neurology-and-immunology/multiple-sclerosis.html. This application and its content are directed exclusively to health professionals, empowered to prescribe medications and to representatives authorized by the MEDICAL USER in Argentina, Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Panama, the Dominican Republic, the Republic of Colombia, Chile, the Republic of Ecuador, the United Mexican States and the Republic of Peru. If you are not a health professional or an authorized representative of the MEDICAL USER, we ask you to refrain from using it. This application requires specialized training for its handling and interpretation. [2022] MERCK KGaA || © All rights reserved.